Apalutamide Plus Immunotherapy Combo Trial for Rare Prostate Cancer Variant Terminated

Treatment-emergent small cell neuroendocrine prostate cancer (t-SCNC) represents one of the most lethal resistance mechanisms to modern androgen deprivation therapies. As prostate cancers evolve under the selective pressure of AR-targeted drugs, a subset undergo lineage plasticity, transforming into AR-indifferent neuroendocrine tumors with dramatically worsened prognosis and limited treatment options.

Despite this transformation away from AR-driven signaling, most t-SCNC tumors continue to express AR protein, suggesting epigenetic reprogramming rather than complete AR loss. This residual expression provided the scientific rationale for this Phase 2 trial, which was designed to test whether continued AR blockade with apalutamide could complement immune checkpoint inhibition via cetrelimab to generate meaningful anti-tumor responses.

The trial was designed to enroll patients with metastatic castration-resistant prostate cancer and biopsy-confirmed evidence of neuroendocrine transformation. The primary goal was to achieve a clinically significant composite response rate with durable benefit. According to the ClinicalTrials.gov registration, the trial status is listed as terminated. The publicly available record does not disclose the reason for termination, nor does it report enrollment numbers, efficacy, or safety outcomes.

Because no results have been released, no conclusions can be drawn about whether the combination produced any clinical benefit or whether termination was driven by futility, safety, enrollment difficulties, or administrative factors. Caution is warranted against interpreting termination as evidence of biological failure.

Nonetheless, t-SCNC continues to represent a major unmet clinical need. Ongoing research into platinum-based chemotherapy combinations, EZH2 inhibitors, Aurora kinase A inhibitors, and other lineage plasticity-targeted agents may eventually yield more effective strategies. The persistent AR expression in these tumors remains a biologically intriguing but, so far, therapeutically elusive target.